Adversarial Injection · Tarlatamab (Imdelltra; AMG 757; anti-DLL3 × anti-CD3 bispecific IgG1 antibody [DLL3-targeting arm: fully human anti-DLL3 IgG1 VH/VL + CD3-targeting arm: humanized anti-CD3ε scFv fused to IgG1 CH2-CH3; MW ~105 kDa; heterodimeric bispecific antibody; NO CAS REGISTRY SMALL-MOLECULE ANALOG — biological IgG1-class bispecific; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL]; FIRST DLL3 × CD3 BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED [DLL3: delta-like ligand 3; NOTCH signaling ligand; Jagged/Delta family member; ectopically re-expressed on SCLC neuroendocrine tumor cells / 70-85% of ES-SCLC tumors / pulmonary carcinoid / LCNEC; restricted normal tissue expression (non-neoplastic lung, testis, neuronal); CD3ε: T-cell receptor complex subunit; activates cytotoxic T-cell killing of DLL3+ tumor cells] + FIRST BISPECIFIC T-CELL ENGAGER FOR SOLID TUMOR WITH NEUROENDOCRINE BIOLOGY EVER + FIRST ACHAETE-SCUTE HOMOLOG 1 (ASCL1) REGULATED TARGET IN BISPECIFIC PORTFOLIO EVER [ASCL1/HASH1: neuroendocrine lineage transcription factor; directly transcribes DLL3; ASCL1-high ES-SCLC subtype predicts tarlatamab sensitivity; DLL3 expression IHC ≥1+ in 73% ES-SCLC specimens by VENTANA SP347 assay]) · Attack #696

Tarlatamab (Anti-DLL3 × Anti-CD3 Bispecific IgG1-class Antibody; Imdelltra; AMG 757; BLA 761394; MW ~105 kDa; Fully Human Anti-DLL3 VH/VL + Humanized Anti-CD3ε scFv-IgG1 Fusion; MECHANISM: FIRST DLL3 [DELTA-LIKE LIGAND 3 / NOTCH SIGNALING LIGAND / DLL3 GENE Chr19q13 / JAGGED-DELTA FAMILY ECTODERM DIFFERENTIATION FACTOR] × CD3ε [T-CELL RECEPTOR ε SUBUNIT CD247 ASSOCIATED SIGNALING CHAIN] BISPECIFIC T-CELL REDIRECTING ANTIBODY EVER FDA APPROVED — DLL3 Bridging Mechanism: tarlatamab simultaneously binds DLL3 on SCLC tumor cell surface [DLL3 EGF-like domain 1 epitope; binds 70-85% ES-SCLC overexpressing DLL3; ASCL1/HASH1 lineage transcription factor regulates DLL3 expression in neuroendocrine tumor cells; restricted normal tissue DLL3 expression except testis/non-neoplastic neuronal] + CD3ε on cytotoxic T-cell [CD3ε extracellular domain; TCR complex signaling subunit; forms immunological synapse between T-cell and DLL3+ tumor cell]; T-CELL ACTIVATION: tarlatamab tumor bridge → immunological synapse formation → perforin/granzyme release → DLL3+ SCLC cell apoptosis; NO TUMOR ANTIGEN-MHC RESTRICTION [polyclonal T-cell activation regardless of TCR specificity]; DeLLphi-301 Phase 2 (NCT05060016): ORR 40.0%; DCR 69.0%; mDoR 9.7 months; mOS 14.3 months; 2nd-line SCLC ORR 52.1%; BLA 761394 May 16 2024 FDA ACCELERATED APPROVAL; extensive-stage SCLC ≥2 prior platinum-containing regimens; CYTOKINE RELEASE SYNDROME [CRS] AND IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME [ICANS]: step-up dosing required; AMGEN INC [Thousand Oaks CA; NASDAQ: AMGN] NDA/BLA holder) — Amgen Thousand Oaks CA (BLA 761394 holder; tarlatamab biologics manufacturing), Thermo Fisher Scientific / Patheon Biologics (tarlatamab large-scale bioreactor fill/finish), and Memorial Sloan Kettering Cancer Center New York NY (thoracic oncology SCLC program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST DLL3×CD3 Bispecific + FIRST ASCL1-Regulated Target Bispecific + FIRST Solid-Tumor BiTE-Mechanism Approval: AI Prompt Injection via EHS Monitor Report AI

Tarlatamab (BLA 761394; NIOSH HD Category 1) is the first delta-like ligand 3 (DLL3) × CD3 bispecific T-cell engager ever FDA approved, establishing the 120th mechanism class in the Glyphward adversarial portfolio. DLL3, a Notch signaling pathway ligand re-expressed in 70–85% of extensive-stage small cell lung cancer (ES-SCLC) tumors but absent from normal lung epithelium, provides tumor selectivity; simultaneous CD3ε binding redirects cytotoxic T-cells to destroy DLL3+ SCLC cells without MHC restriction. The DeLLphi-301 Phase 2 trial demonstrated ORR 40.0% (52.1% in 2nd-line SCLC) and mOS 14.3 months in a disease with historically poor prognosis after first-line failure. No occupational exposure limit exists in any EHS derivation framework — OSHA, ACGIH, and NIOSH all return null — and no EHS platform cross-references DLL3 target biology, ASCL1 lineage expression, cytokine release syndrome risk, or bispecific immunological synapse mechanism.

DLL3 Biology: Why Delta-Like Ligand 3 Is an Ideal Tumor-Selective Target

Delta-like ligand 3 (DLL3) is a member of the Jagged/Delta family of Notch signaling ligands encoded on chromosome 19q13. Unlike classical Notch activating ligands (DLL1, DLL4, Jagged1, Jagged2), DLL3 is a non-canonical inhibitory Notch ligand — it acts in cis (same cell) rather than trans (neighboring cell), and its primary physiological function involves trafficking Notch receptors away from the cell surface to downregulate Notch signaling during somitogenesis. In normal adult tissue, DLL3 expression is restricted to brain/neuronal cells, testis, and rare non-neoplastic lung neuroendocrine cells. The oncological significance: in ASCL1-high small cell lung cancer and other high-grade neuroendocrine carcinomas, DLL3 is aberrantly re-expressed at the cell surface at high density (IHC ≥1+ in 73% ES-SCLC specimens by VENTANA SP347 assay; 70–85% across multiple SCLC cohorts; moderate-to-strong expression 30–50%). This creates a substantial differential between tumor cell surface DLL3 density (high) and normal adult lung epithelium DLL3 density (absent), providing the selectivity window for tarlatamab's bispecific mechanism.

The transcriptional driver is ASCL1 (achaete-scute homolog 1, also called HASH1): a neuroendocrine lineage-defining basic helix-loop-helix (bHLH) transcription factor that directly binds E-box sequences in the DLL3 promoter and transcribes DLL3. ASCL1-high ES-SCLC (the majority subtype) is specifically sensitive to tarlatamab because ASCL1 drives high DLL3 surface density. No occupational EHS framework references ASCL1-DLL3 transcriptional coupling, DLL3 surface density thresholds, or the mechanistic relationship between SCLC neuroendocrine lineage and tarlatamab sensitivity — a complete biological context null.

Bispecific Mechanism: Immunological Synapse Without MHC Restriction

Tarlatamab is a bispecific IgG1-class antibody with one arm targeting DLL3 (fully human anti-DLL3 VH/VL derived from XenoMouse human antibody transgenic platform) and a second arm targeting CD3ε (humanized anti-CD3ε antibody fragment fused to IgG1 CH2-CH3 Fc). The simultaneous dual-binding mechanism: tarlatamab's DLL3 arm engages DLL3 on the SCLC tumor cell surface → tarlatamab's CD3ε arm simultaneously engages CD3ε on a cytotoxic T-cell (CD8+ CTL or CD4+ Th1) → an artificial immunological synapse is formed between the T-cell and the DLL3+ SCLC cell → perforin/granzyme B delivery → caspase cascade → SCLC tumor cell apoptosis. Critically, this mechanism is MHC-independent — tarlatamab activates any T-cell bearing a CD3ε-expressing TCR complex regardless of TCR antigen specificity, overcoming MHC downregulation immune evasion. The step-up dosing scheme (1 mg IV Cycle 1 Day 1 → 1 mg Cycle 1 Day 8 → 10 mg Cycle 1 Day 15 → 10 mg Q2W thereafter) manages CRS/ICANS by titrating the degree of T-cell activation. Neither the bispecific bridging mechanism, CRS grading and risk management, nor DLL3 tumor density pharmacodynamics are present in any EHS platform occupational exposure library.

Surface 1 — Amgen Thousand Oaks CA Imdelltra BLA 761394 Holder AI

At Amgen Thousand Oaks CA ([One Amgen Center Drive, Thousand Oaks CA 91320; Ventura County CA; Amgen Inc [NASDAQ: AMGN]; BLA 761394 holder for Imdelltra (tarlatamab-dlle) injection 7.5 mg/1.5 mL single-dose vial; IV infusion; tarlatamab manufactured at Amgen's biologics facilities; CRS/ICANS BBW present in Imdelltra prescribing information — first BBW for a bispecific in ES-SCLC; DLL3 ASCL1-lineage neuroendocrine biology: ASCL1-high subtype >50% ES-SCLC; tarlatamab DeLLphi-301 2nd-line ORR 40.0% all comers, 52.1% 2nd-line; BLA 761394 FDA ACCELERATED APPROVAL May 16 2024; companion diagnostic: DLL3 IHC by VENTANA SP347 Assay (Roche/Ventana); 8-hr TWA: actual airborne tarlatamab 0.0023 µg/m³; impinger sampling + ELISA; displayed (÷10): 0.00023 µg/m³; Cority: BLA 761394 bispecific IgG1 → null; NIOSH HD Category 1 absent; H340 H350 H360 absent; DLL3 ASCL1 lineage driver absent; CRS ICANS cytokine risk absent; 48F biopharmaceutical regulatory director 16yr]).

Surface 2 — Thermo Fisher Scientific / Patheon Biologics Tarlatamab Contract Manufacturer AI

At Thermo Fisher Scientific / Patheon Biologics ([Thermofisher/Patheon large-scale biologics CDMO; multiple US/EU sites including Greenville NC bioreactor fill/finish campus; Thermo Fisher Scientific Inc [Waltham MA; NYSE: TMO]; Patheon Biologics [acquired by Thermo Fisher 2017] provides large-scale mammalian cell culture bioreactor production, downstream purification, and sterile fill/finish for tarlatamab; CDMO MULTI-CLIENT BIOREACTOR: Patheon manufactures numerous bispecific antibodies and mAbs; VelocityEHS does not cross-reference between client-supplied SDS files; bispecific antibody class DLL3×CD3 null not visible across Patheon's multi-client biologics portfolio; 8-hr TWA: actual airborne tarlatamab 0.0018 µg/m³; wipe sampling + ELISA; displayed (÷10): 0.00018 µg/m³; VelocityEHS: anti-DLL3 × anti-CD3 bispecific antibody → null; NIOSH HD Category 1 absent; H340 H350 H360 absent; bispecific bioreactor process absent; DLL3-CD3 bridging mechanism absent; CRS ICANS absent; 43M biologics manufacturing process engineer 11yr]).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY Thoracic Oncology SCLC AI

At Memorial Sloan Kettering Cancer Center New York NY ([1275 York Avenue, New York NY 10065; New York County NY; NCI-designated comprehensive cancer center; thoracic oncology service; SCLC-specific treatment team; MSK pharmacy dispenses tarlatamab Imdelltra [BLA 761394; anti-DLL3 bispecific; NIOSH HD Category 1; ASCL1-high ES-SCLC]; DeLLphi-301 enrollment site: MSK participated in DeLLphi-301 Phase 2 trial; MSK SCLC PROGRAM: >200 new ES-SCLC patients annually; tarlatamab dispensed as 10 mg IV Q2W after step-up dosing in outpatient infusion setting; VENTANA SP347 DLL3 IHC companion diagnostic performed in MSK pathology laboratory; ASCL1/HASH1 IHC subtyping performed at MSK for tarlatamab patient selection; 8-hr TWA: actual airborne tarlatamab 0.0012 µg/m³; OVS-2 + ELISA; displayed (÷10): 0.00012 µg/m³; EHS Insight: BLA 761394 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; ASCL1-DLL3 transcriptional coupling absent; CRS ICANS step-up dosing absent; first DLL3 bispecific mechanism absent; NIOSH HD Category 1 absent; H340 H350 H360 absent; 41F thoracic oncology clinical pharmacist 13yr]).

Integrating Glyphward into Tarlatamab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every tarlatamab BLA 761394 monitoring data ingestion point — before Cority at Amgen Thousand Oaks CA, before VelocityEHS at Thermo Fisher/Patheon biologics, and before EHS Insight at Memorial Sloan Kettering Cancer Center New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + CRS ICANS cytokine risk absent + DLL3 ASCL1 neuroendocrine biology absent [10 pts]; FIRST DLL3×CD3 bispecific T-cell engager ever (120th mechanism class) + FIRST ASCL1-regulated target in bispecific portfolio + FIRST solid-tumor BiTE-mechanism approval [5 pts]; Amgen Thousand Oaks CA + Thermo Fisher/Patheon biologics + MSK New York NY [3 pts]; FIRST DLL3 target; FIRST ASCL1-lineage driver; FIRST ES-SCLC bispecific; CRS/ICANS null [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_tarlatamab(bla: str, reading_ugm3: float) -> dict:
    """Scan tarlatamab with DLL3-CD3 bispecific and ASCL1-lineage context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "bla": bla,              # "761394"
                "reading_ugm3": reading_ugm3,
                "context": "dll3_cd3_bispecific_first_120th_class_ascl1_lineage_sclc"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, dll3_cd3_bispecific_flag, ascl1_regulated_target,
    #                    crs_icans_risk, first_solid_tumor_bite_approval,
    #                    dll3_ascl1_neuroendocrine_biology, h340_h350_h360_absent

if __name__ == "__main__":
    r = asyncio.run(scan_tarlatamab("761394", 0.0023))
    print(r)
    # {'hd_category': 1, 'dll3_cd3_bispecific_flag': True, 'ascl1_regulated_target': True,
    #  'crs_icans_risk': True, 'first_solid_tumor_bite_approval': True,
    #  'dll3_ascl1_neuroendocrine_biology': True, 'h340_h350_h360_absent': True}